Saturday 13 September 2014

Sanofi aims to grow Genzyme unit with new drugs and acquisitions

In the 10th paragraph, the quote should be attributed to Bill Sibold, not Mike Panzara) Sanofi rare disease unit Genzyme hopes to become a leader in the multiple sclerosis (MS) field with the help of new products developed in-house but also through acquisitions, senior Genzyme executives told Reuters. The Cambridge, Massachusetts company is confident in the commercial success of its two MS drugs Lemtrada and Aubagio and is "very active" in its hunt for external growth, Bill Sibold, the head of Genzyme's MS franchise, told Reuters. He declined to comment on potential targets but said Genzyme was looking to snap up truly innovative products, was regularly talking to other companies and constantly weighing its options. via Health News Headlines - Yahoo News Read More Here..

No comments:

Post a Comment